CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...
Phase 3
Warsaw, Poland and 73 other locations
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...
Phase 3
Warszawa, Poland and 161 other locations
This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily o...
Phase 2
Warszawa, Poland and 37 other locations
the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...
Phase 3
Warsaw, Poland and 36 other locations
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...
Phase 2
Warszawa, Poland and 75 other locations
(IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with m ...
Phase 1
Warszawa, Poland and 23 other locations
effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (Qo...
Phase 3
Warszawa, Poland and 20 other locations
with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...
Phase 3
Warszawa, Poland and 121 other locations
The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in subjects who completed Week 96 in Part 1 of Study 109MS306...
Phase 3
Warszawa, Poland and 61 other locations
) neo-antigen in subjects with relapsing multiple sclerosis (RMS)....
Phase 3
Warszawa, Poland and 301 other locations
Clinical trials
Research sites
Resources
Legal